Physician profile
Brian Coder
NPI 1427164888
$1,453.33
in general payments reported to CMS, 2019-2025
27 companies · $34.84 in 2025
The $34.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $140 · 2021: $448 · 2022: $393 · 2023: $64.44 · 2024: $144 · 2025: $34.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $387.29 | 2021-2024 | Vraylar |
| Lilly USA, LLC | $142.24 | 2019-2024 | Jardiance, Zepbound |
| Novo Nordisk INC | $140.29 | 2019-2021 | |
| Abbott Laboratories | $134.24 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $62.56 | 2021-2022 | |
| Pfizer INC. | $54.44 | 2019-2025 | |
| Glaxosmithkline, LLC. | $44.81 | 2020-2022 | |
| Sanofi Pasteur INC. | $42.79 | 2021-2022 | |
| Allergan, INC. | $41.19 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.12 | 2021-2024 | Xifaxan |
| Edwards Lifesciences Corporation | $37.85 | 2023 | |
| Supernus Pharmaceuticals, INC. | $35.72 | 2022 | |
| Biofire Diagnostics, LLC | $35.30 | 2019 | |
| Currax Pharmaceuticals LLC | $30.15 | 2021-2022 | |
| Boston Scientific Corporation | $28.12 | 2024 | Ams 700 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $27.09 | 2021 | |
| Pharmacosmos Therapeutics INC. | $18.84 | 2022 | |
| Inspire Medical Systems, INC. | $18.43 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $18.19 | 2024 | Airsupra |
| Althera Pharmaceuticals LLC | $16.37 | 2021 | |
| Nevro Corp. | $16.08 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.84 | 2024 | Voquezna |
| Shire North American Group INC | $14.45 | 2019 | |
| Antares Pharma, INC. | $13.93 | 2024 | Xyosted |
| Mylan Specialty L.P. | $12.83 | 2023 | Yupelri |
| Alk-Abello, INC | $12.60 | 2019 | |
| Amgen INC. | $12.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Coder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.